Clinical Phenotypes Associated With Cerebral Small Vessel Disease: An Overview of Systematic Reviews.

Neurology

From the School of Cardiovascular and Metabolic Health (A.K.K., T.J.Q.), University of Glasgow; Centre for Clinical Brain Sciences (J.M.W.), University of Edinburgh; and School of Health & Wellbeing (D.M.L.), University of Glasgow, United Kingdom.

Published: April 2024

AI Article Synopsis

  • - The study provides a comprehensive overview of the clinical manifestations of cerebral small vessel disease (cSVD), which is linked to strokes and cognitive impairment, by analyzing existing systematic reviews across different body systems.
  • - Researchers examined 6,156 publications and ultimately included 24 systematic reviews encompassing over 1.1 million participants, focusing primarily on cognitive and neuropsychiatric symptoms associated with cSVD.
  • - The findings highlighted a gap in literature regarding certain aspects of cSVD, such as specific assessments for lacunes and small subcortical infarcts, as well as limited reviews on peripheral nervous system and gastrointestinal symptoms.

Article Abstract

Background And Objectives: Cerebral small vessel disease (cSVD) causes lacunar and hemorrhagic stroke and is an important contributor to vascular cognitive impairment. Other potential physical and psychological consequences of cSVD have been described across various body systems. Descriptions of cSVD are available in journals specific to those individual body systems, but a comprehensive assessment of clinical manifestations across this disparate literature is lacking. We conducted an overview of systematic reviews describing clinical cSVD phenotypes.

Methods: We searched multidisciplinary databases from inception to December 2023. We included reviews describing concurrent clinical phenotypes in individuals with neuroimaging evidence of cSVD, defined using the STandards for ReportIng Vascular changes on nEuroimaging criteria. We broadly classified phenotypes into cognitive, mood and neuropsychiatric, respiratory, cardiovascular, renal-urinary, peripheral nervous system, locomotor, and gastrointestinal. We included both studies assessing multiple cSVD features and studies examining individual cSVD markers. We extracted risk factor-adjusted effect estimates, where possible, and assessed methodologic quality using the Assessment of Multiple Systematic Reviews-2 tool.

Results: After screening 6,156 publications, we included 24 systematic reviews reporting on 685 original studies and 1,135,943 participants. Cognitive and neuropsychiatric phenotypes were examined most often, particularly in relation to white matter hyperintensities (range of risk ratios [RRs] for cognitive phenotypes 1.21-1.49, range of 95% CI 1.01-1.84; for neuropsychiatric, RR 1.02-5.71, 95% CI 0.96-19.69). Two reviews focused solely on perivascular spaces. No reviews assessed lacunes or small subcortical infarcts separately from other cSVD features. Reviews on peripheral nervous system, urinary, or gastrointestinal phenotypes were lacking. Fourteen reviews had high methodologic quality, 5 had moderate quality, and 5 had low quality. Heterogeneity in cSVD definitions and phenotypic assessments was substantial.

Discussion: Neuroimaging markers of cSVD are associated with various clinical manifestations, suggesting a multisystem phenotype. However, features classically associated with cSVD, for example, gait, had limited supporting evidence, and for many body systems, there were no available reviews. Similarly, while white matter hyperintensities were relatively well studied, there were limited data on phenotypes associated with other cSVD features. Future studies should characterize the full clinical spectrum of cSVD and explore clinical associations beyond neurocognitive and neuropsychiatric presentations.

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000209267DOI Listing

Publication Analysis

Top Keywords

csvd
13
systematic reviews
12
body systems
12
csvd features
12
reviews
9
clinical phenotypes
8
phenotypes associated
8
cerebral small
8
small vessel
8
vessel disease
8

Similar Publications

Background: Investigate the correlation between low-density lipoprotein (LDL) cholesterol, homocysteine and cognitive function in patients with cerebral small vessel disease (CSVD).

Methods: 240 patients with CSVD confirmed by head MRI in the Department of Neurology from January 2020 to December 2023 were retrospectively included in the study. All the patients had complete blood biochemical examination, and their cognitive function was evaluated by Montreal Cognitive Assessment Scale (MoCA), and after correcting for the factor of years of education, the patients were divided into a group of normal cognition (MoCA 26, 70 patients) and a group of cognitive function (MoCA 26, 70 patients) according to the scores.

View Article and Find Full Text PDF

Blood-brain barrier breakdown in brain ischemia: Insights from MRI perfusion imaging.

Neurotherapeutics

December 2024

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Neurocritical Care Division, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, MD, United States; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address:

Brain ischemia is a major cause of neurological dysfunction and mortality worldwide. It occurs not only acutely, such as in acute ischemic stroke (AIS), but also in chronic conditions like cerebral small vessel disease (cSVD). Any other conditions resulting in brain hypoperfusion can also lead to ischemia.

View Article and Find Full Text PDF

Metabolic syndrome (MetS) has been linked to accelerated cognitive decline and Alzheimer's disease and related dementias (ADRDs) via cerebral small vessel disease (CSVD); however, this relation in MetS without overt cardiometabolic disease comorbidities is unknown and may represent a population amenable to preventative strategies. Our study aimed to determine risk profiles for neurocognitive decline and ADRDs in early-stage MetS with evidence of CSVD using the TriNetX electronic health records (EHR) research network. Patients aged 50 to 80 years old meeting MetS criteria were identified utilizing TriNetX data from 76 healthcare organizations.

View Article and Find Full Text PDF

Background: Cerebral white matter hyperintensity (WMH) is a pivotal imaging feature of cerebral small vessel disease (CSVD), closely correlated with an elevated risk of ischemic stroke (IS). Trimethylamine N-oxide (TMAO), a metabolite of gut microbiota, is increasingly associated with IS and atherosclerosis. However, the intricate relationship between TMAO and WMH remains ambiguous.

View Article and Find Full Text PDF

Introduction: Cerebral small vessel disease (CSVD) is highly prevalent in elder individuals, and its variable cognitive outcomes indicate some cognitive reserve mechanisms. Contribution from functional network features is still unclear. Here we explore how functional segregation-integration preference influences the cognitive changes against CSVD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!